UBS Group
DMK

UBS Group’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

UBS Group’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,562
Closed -$1.09K – 10401
2023
Q4 		$1.09K Buy
1,562
+1,370
+714% +$795 ﹤0.01% 8404
2023
Q3 		$132 Sell
192
-94
-33% -$120 ﹤0.01% 8820
2023
Q2 		$689 Sell
286
-1,545
-84% -$6.6K ﹤0.01% 8132
2023
Q1 		$14.9K Buy
1,831
+1,246
+213% +$16.5K ﹤0.01% 7316
2022
Q4 		$6.96K Buy
+585
New +$6.69K ﹤0.01% 8960
2022
Q3 		– Sell
-1,228
Closed -$43K – 11254
2022
Q2 		$43K Buy
1,228
+276
+29% +$8.61K ﹤0.01% 6050
2022
Q1 		$39K Sell
952
-1,124
-54% -$48.2K ﹤0.01% 6747
2021
Q4 		$89K Buy
2,076
+1,362
+191% +$85K ﹤0.01% 6421
2021
Q3 		$49K Sell
714
-139
-16% -$10.2K ﹤0.01% 6360
2021
Q2 		$66K Buy
853
+139
+19% +$8.47K ﹤0.01% 6192
2021
Q1 		$47K Sell
714
-269
-27% -$20.9K ﹤0.01% 6636
2020
Q4 		$33K Buy
983
+841
+592% +$37.4K ﹤0.01% 6563
2020
Q3 		$8K Sell
142
-738
-84% -$43.8K ﹤0.01% 7055
2020
Q2 		$33K Buy
880
+713
+427% +$24.4K ﹤0.01% 6206
2020
Q1 		$4K Sell
167
-164
-50% -$6.96K ﹤0.01% 7429
2019
Q4 		$17K Buy
331
+242
+272% +$11.7K ﹤0.01% 7009
2019
Q3 		$5K Buy
89
+17
+24% +$1.22K ﹤0.01% 7504
2019
Q2 		$7K Hold
72
– – ﹤0.01% 7264
2019
Q1 		$11K Hold
72
– – ﹤0.01% 6768
2018
Q4 		$11K Sell
72
-50
-41% -$9.59K ﹤0.01% 7202
2018
Q3 		$30K Sell
122
-53
-30% -$12.5K ﹤0.01% 6552
2018
Q2 		$39K Buy
175
+80
+84% +$21.4K ﹤0.01% 6198
2018
Q1 		$23K Buy
95
+88
+1,257% +$23.1K ﹤0.01% 6320
2017
Q4 		$2K Sell
7
-23
-77% -$7.57K ﹤0.01% 7643
2017
Q3 		$11K Buy
30
+23
+329% +$8.16K ﹤0.01% 6844
2017
Q2 		$2K Hold
7
– – ﹤0.01% 7411
2017
Q1 		$2K Sell
7
-11
-61% -$2.78K ﹤0.01% 7319
2016
Q4 		$4K Buy
18
+11
+157% +$2.21K ﹤0.01% 7348
2016
Q3 		$2K Hold
7
– – ﹤0.01% 7434
2016
Q2 		$1K Sell
7
-1
-13% -$461 ﹤0.01% 7587
2016
Q1 		$3K Buy
+8
New +$2.86K ﹤0.01% 7219
2015
Q4 		– Sell
-12
Closed -$3K – 8637
2015
Q3 		$3K Sell
12
-36
-75% -$10K ﹤0.01% 7977
2015
Q2 		$14K Buy
+48
New +$14.5K ﹤0.01% 7203

Other funds holding DMK

CPA
Clear Point Advisors Melville, New York $129M AUM 12.02% 1-Year Est. Return
OPTFSNA
Old Point Trust & Financial Services N A Newport News, Virginia $311M AUM 24.14% 1-Year Est. Return

UBS Group's DMK Position: Q1 2024 in Review

UBS Group sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 1,562 shares — an estimated $1.09K sold.

UBS Group first reported a position in DMK in Q2 2015 and held it in 33 quarters. The position peaked at $89K in Q4 2021. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.

  • UBS Group reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
  • UBS Group sold 1,562 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $1.09K.
  • UBS Group first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2015 and held it in 33 quarters.
  • UBS Group's DMK Pharmaceuticals Corporation Common Stock position peaked at $89K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.